A Study of Propranolol to Treat Kaposi Sarcoma

Status Not yet recruiting

Clinical Trial Summary

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.

Clinical Trial Description

Eligible study participants will receive propanolol twice daily for an initial 12-week period. At the conclusion of 12-weeks, response will be assessed. Participants who achieve a complete or partial response will continue propanolol for an additional 6 weeks or 12 weeks, respectively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05797662
Study type	Interventional
Source	AIDS Malignancy Consortium
Contact	Shane McAllister, Md, Phd
Phone	612-301-2205
Email	smcallis@umn.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	July 1, 2025
Completion date	August 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06445166` - Propranolol for the Treatment of Kaposi Sarcoma in Adults	Phase 2
Recruiting	`NCT04941274` - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	Phase 1/Phase 2
Completed	`NCT03160183` - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting	`NCT03993106` - A Study of sEphB4-HSA in Kaposi Sarcoma	Phase 2
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Completed	`NCT00395278` - Development of Serologic Assays for Human Herpes Virus-8
Recruiting	`NCT02408861` - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Completed	`NCT03296553` - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.	Phase 2
Recruiting	`NCT04305691` - Trial of Ixazomib for Kaposi Sarcoma	Phase 2
Completed	`NCT03316274` - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	Early Phase 1
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Terminated	`NCT04893018` - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV	Phase 1
Recruiting	`NCT06375122` - Natural History Study of Kaposi Sarcoma
Recruiting	`NCT05663502` - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting	`NCT05329792` - L19IL2/L19TNF in Skin Cancer Patients	Phase 2
Not yet recruiting	`NCT05411237` - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma	Phase 3
Completed	`NCT03050788` - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma	N/A
Completed	`NCT03404297` - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya	N/A
Terminated	`NCT01412515` - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma	Phase 2
Not yet recruiting	`NCT06004011` - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)	N/A